Related Experiment Video
Updated: Mar 16, 2026
Rapid Detection of Fecal Antigen of Helicobacter pylori Infection Based on Double Antibody Sandwich Detection Technology
Published on: May 23, 2025
EUROHELICAN-The First Helicobacter Pylori Screen-and-Treat Population-Based Study in Young Adults in Europe
Bojan Tepeš1,2, Tatjana Kofol Bric1, Jernej Završnik3
1National Institute for Public Health, Ljubljana, Slovenia.
Background:
Most gastric cancer cases are attributable to chronic Helicobacter pylori (H. pylori) infection and can theoretically be prevented.
Objective:
In the EUROHELICAN project, we aimed to assess the feasibility, acceptability, effectiveness, and adverse events of a Helicobacter pylori screen-and-treat program in the 30-34-year age group for the first time in Europe.
Design:
The study was conducted in the Community Healthcare Center dr. Adolf Drolc Maribor, following the methodology prepared by the National Institute of Public Health. We invited asymptomatic individuals aged 30-34 to be tested for H. pylori IgG antibodies; positive results were confirmed by urea breath test (UBT).
Results:
2102 participants accepted the invitation. The response rate was 24.4% (95% CI: 23.2-25.5), which was higher in women-28.1% (95% CI: 26.4-29.8) than in men-20.5% (95% CI: 0.19.0-22.1, p < 0.001). The serological prevalence of H. pylori infection was 14.2% (95% CI: 12.7-15.9). A confirmatory urea breath test (UBT) was positive in 83.7% of serology-positive patients. The eradication rate of 14-day bismuth-based quadruple therapy (esomeprazole 40 mg BID, amoxicillin 500 mg, metronidazole 400 mg and bismuth oxide 120 mg, all QID) was 94.7% (95% CI: 89.5-97.9). Adverse events (AEs) during treatment were reported more frequently in women (38.8%, 95% CI: 28.1-50.3) than in men (21.5%, 95% CI: 12.3-33.5; p < 0.05).
Conclusion:
H. pylori screening and-treat program in 30-34 age group in Slovenia is feasible; H. pylori treatment is very effective with acceptable rate of AEs. Different approaches to raising public awareness are needed to increase participation rates.
Trial Registration:
EU PAS number of HMA-EMA RWD Catalog: EUPAS107327, Study ID: 108428; ClinicalTrials.gov ID: NCT06216639, Protocol ID: EUROHELICAN01.
More Related Videos
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients